CMS HIV Serologic Testing Coverage Policy Updated: What Billers Need to Know About NCD 265
CMS has modified National Coverage Determination 265, which governs Medicare coverage for serologic testing used to detect HIV antibodies. This update affects how diagnostic labs, infectious disease practices, and primary care offices document and bill for ELISA and confirmatory Western blot testing. If your revenue cycle team processes claims for HIV diagnostic workups, understanding the exact coverage thresholds in this policy is essential to avoid denials.
| Field | Detail |
|---|---|
| Payer | CMS (Medicare) |
| Policy | Serologic Testing for Acquired Immunodeficiency Syndrome (AIDS) |
| Policy Code | NCD 265 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | Medium |
| Specialties Affected | Infectious Disease, Internal Medicine, Primary Care, Clinical Laboratory, Public Health Clinics |
| Key Action | Confirm that two reactive ELISA results are documented on the same specimen before billing for confirmatory Western blot testing. |
What CMS NCD 265 Covers: HIV Serologic Testing Criteria
The Centers for Medicare & Medicaid Services governs HIV serologic testing coverage under NCD 265 within the Diagnostic Laboratory Tests benefit category. The policy addresses testing used to detect antibodies to the human immunodeficiency virus (HIV)—historically referred to in clinical documentation and older billing records as human T-cell lymphotropic virus, type III (HTLV-III). Both terms remain in active use, and your documentation may reference either.
The core coverage rule is straightforward but has a critical sequence requirement: Medicare covers serologic testing only when it is performed to support diagnosis in symptomatic patients. This is not a blanket lab benefit. The clinical indication must reflect active signs or symptoms consistent with HIV disease—not routine risk-based screening in an asymptomatic individual.
The ELISA-to-Western Blot Sequence: A Hard Billing Requirement
This is where most claim errors happen. CMS NCD 265 establishes a specific testing sequence that must be satisfied before Medicare will reimburse for confirmatory testing:
- An initial enzyme-linked immunosorbent assay (ELISA) is performed.
- If reactive, the same specimen must be retested with a second ELISA.
- Only if both ELISA tests on that same specimen are positive will CMS cover the confirmatory test—typically a Western blot or immunofluorescent assay (IFA).
This is not a soft guideline. The policy is explicit: two ELISA tests conducted on the same specimen must both return positive results before Medicare will cover the Western blot. Submitting a Western blot claim when only one ELISA was performed—or when the two ELISAs were run on different specimens—will result in a denial.
Labs and reference lab billing teams should audit their order workflows to confirm that this specimen-matching requirement is being tracked and documented before confirmatory test claims go out.
What CMS Will NOT Cover: Screening vs. Diagnostic Testing
The distinction between diagnostic and screening intent is the most consequential coverage line in NCD 265. Serologic HIV testing is not covered when furnished as part of a screening program for asymptomatic individuals.
This means that if a patient presents with no symptoms and the order is driven by risk factors alone—sexual history, occupational exposure, routine wellness lab panel—the claim does not meet Medicare's medical necessity threshold under this NCD. These services may fall under separate Medicare preventive benefit provisions, but they do not qualify under NCD 265.
For billing and coding purposes, the ICD-10-CM diagnosis code attached to the claim must reflect symptomatic presentation. Coding to a rule-out or exposure code when the patient is asymptomatic will not satisfy medical necessity under this policy and risks both denial and potential compliance exposure.
Documentation Requirements That Support Medical Necessity
Because the symptomatic threshold is the gateway to coverage, clinical documentation needs to clearly support that gateway. Billing managers should work with clinical staff to ensure that the following elements are present in the medical record before claims are submitted:
| # | Covered Indication |
|---|---|
| 1 | Chief complaint and presenting symptoms that are consistent with HIV-related illness or immunocompromised presentation |
| 2 | Ordering physician's clinical rationale connecting the serologic test to the diagnostic workup for the symptomatic patient |
| 3 | Specimen documentation that ties both ELISA results to the same specimen collection, particularly if Western blot confirmation is being billed |
Insufficient documentation is the second most common cause of denial on these claims, right behind the specimen-matching failure on the ELISA sequence.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy document for NCD 265 does not list specific CPT or HCPCS codes within the policy text itself. No codes are enumerated in the current version of this NCD.
Billing teams should reference the CMS Claims Processing Instructions cross-referenced in this NCD for applicable codes, and consult their lab fee schedule and local Medicare Administrative Contractor (MAC) guidance for the specific CPT codes used to bill ELISA and Western blot testing. Your MAC may have issued a related Local Coverage Determination (LCD) that provides the code-level detail NCD 265 does not.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Audit your Western blot claim workflow immediately (before March 12, 2026). Pull any existing claim templates or order sets that trigger Western blot billing and confirm they include a documentation checkpoint requiring two positive ELISA results on the same specimen. This single requirement is the most common failure point under this policy. |
| 2 | Review your ICD-10-CM coding practices for HIV diagnostic testing. Ensure your coding team understands that asymptomatic patients do not qualify for coverage under NCD 265. Flag any claim where the diagnosis code does not reflect symptomatic presentation for a pre-submission review step. |
| 3 | Contact your MAC for the applicable CPT code list. Since NCD 265 does not enumerate specific codes, reach out to your Medicare Administrative Contractor or review their website for lab policy bulletins tied to this NCD. Request a current list of covered CPT codes for ELISA and confirmatory testing to ensure your charge description master (CDM) is aligned. |
| 4 | Educate ordering providers on documentation requirements. Send a brief internal policy memo to infectious disease, internal medicine, and primary care physicians explaining that Medicare requires documented symptomatology—not just clinical risk—to support medical necessity for HIV serologic testing billed under NCD 265. |
| 5 | Set a calendar reminder to recheck this NCD post-effective date. Modified NCDs can trigger additional MAC bulletins or transmittals in the weeks following the effective date. Assign someone on your RCM team to monitor for supplemental guidance from CMS after March 12, 2026. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.